Results 301 to 310 of about 66,239 (358)

Managing Pulmonary Embolism Associated With Renal Vein Thrombosis During Nephrotic Syndrome: Usefulness of Rivaroxaban Level Monitoring. [PDF]

Respirol Case Rep
De Masi De Luca G, Naticchia A, Palamà Z, Maisto C, Longo S, Colopi M, Barba F, De Masi De Luca G, Marazia S, Romano S, Sciarra L.   +10 more
europepmc   +1 more source

Development of several machine learning based models for determination of small molecule pharmaceutical solubility in binary solvents at different temperatures. [PDF]

Sci Rep
Alqarni M, Alqarni A.
europepmc   +1 more source

Oral Rivaroxaban for Symptomatic Venous Thromboembolism [PDF]

New England Journal of Medicine, 2010
Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed ...
Rupert M Bauersachs, Scott D Berkowitz, Giancarlo Agnelli   +2 more
exaly   +10 more sources

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

New England Journal of Medicine, 2011
Manesh R Patel, Daniel E Singer, Werner Hacke   +2 more
exaly   +3 more sources

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

New England Journal of Medicine, 2017
John W. Eikelboom, Stuart J Connolly, Jackie J Bosch   +2 more
exaly   +2 more sources

Rivaroxaban in Peripheral Artery Disease after Revascularization

New England Journal of Medicine, 2020
BACKGROUND Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this context are uncertain.
Marc P Bonaca, Rupert M Bauersachs, Sonia Anand   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study.

American Journal of Kidney Diseases, 2023
RATIONALE & OBJECTIVE Head-to-head data comparing the effectiveness and safety of oral anticoagulants in patients with atrial fibrillation (AF) and advanced CKD are lacking. We compared the safety and effectiveness of warfarin or rivaroxaban vs. apixaban
Edouard L. Fu, R. Desai, Julie M. Paik, D. H. Kim, Yichi Zhang, Julianna M Mastrorilli, Alex Cervone, K. J. Lin   +7 more
semanticscholar   +1 more source

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

New England Journal of Medicine, 2018
Background Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke ...
Hardi Mundl, Scott E Kasner, Shrikant I Bangdiwala   +2 more
exaly   +2 more sources